Close search box Search

Oxford Cannabinoid Technologies

Unlocking the medical potential of cannabinoids

Year

2017

Type

NewCo Establishment

Sector

Life Sciences

Founded by Kingsley in 2017, OCT is a next generation cannabinoid-based pharmaceutical firm

Investment Highlights

  • OCT’s vision is to become a global leader in cannabinoid-based prescription medicine, working with world-class academic and commercial partners on research and development, improving the quality of life for millions of patients
  • Whilst changes in legislation have resulted in the creation of cannabis markets across the world, there remains a gap in the development of cannabinoid-based licensed medicines
  • Kingsley founded OCT after agreeing a research partnership with Oxford University. Since then, the company has completed several rounds of funding, including from FTSE 100 company Imperial Brands PLC. In May 2021, OCT completed an IPO on the Main Market of the London Stock Exchange
  • OCT has a lead compound in development across several indications, along with a library of over 400 cannabinoid derivative compounds, both developed internally and licensed from cannabis conglomerate Canopy Growth corporation

The foresight of Kingsley – to invest significant resources and capital in such a progressive market – is enabling us to undertake world-class research in state-of-the-art facilities, led by experts in the field. All of which will help develop new therapies for patients whose needs are not yet met.

Dr. John Lucas
Chief Executive Officer


OCT Press Releases

Oxford Cannabinoid Technologies